Singapore markets open in 2 hours 53 minutes
  • Straits Times Index

    3,173.91
    +9.05 (+0.29%)
     
  • S&P 500

    4,471.37
    +33.11 (+0.75%)
     
  • Dow

    35,294.76
    +382.20 (+1.09%)
     
  • Nasdaq

    14,897.34
    +73.91 (+0.50%)
     
  • BTC-USD

    60,797.47
    +148.34 (+0.24%)
     
  • CMC Crypto 200

    1,464.06
    +57.32 (+4.07%)
     
  • FTSE 100

    7,234.03
    +26.32 (+0.37%)
     
  • Gold

    1,768.10
    -29.80 (-1.66%)
     
  • Crude Oil

    82.66
    +1.35 (+1.66%)
     
  • 10-Yr Bond

    1.5760
    +0.0570 (+3.75%)
     
  • Nikkei

    29,068.63
    +517.70 (+1.81%)
     
  • Hang Seng

    25,330.96
    +368.37 (+1.48%)
     
  • FTSE Bursa Malaysia

    1,598.28
    +5.76 (+0.36%)
     
  • Jakarta Composite Index

    6,633.34
    +7.22 (+0.11%)
     
  • PSE Index

    7,213.46
    +30.35 (+0.42%)
     

Talaris Therapeutics to Participate at Two Upcoming Virtual Investor Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

BOSTON and LOUISVILLE, Ky., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, today announced that members of its senior management team will participate at the following investor conferences:

Morgan Stanley Virtual 19th Annual Global Healthcare Conference
Fireside Chat Date: Monday, September 13, 2021
Time: 5:00 PM ET

SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines 1x1 Event
Date: September 22-23, 2021

A live webcast of the fireside chat at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference will be available on the investors section of the Talaris website at www.talaristx.com. After the live webcast, the event will remain archived on the Talaris website for 90 days.

About Talaris Therapeutics
Talaris Therapeutics, Inc. is a late-clinical stage biopharmaceutical company developing investigational, one-time, allogeneic cell therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders. Talaris maintains corporate offices in Boston, MA, and its cell processing facility in Louisville, KY. For additional information, visit talaristx.com, and follow us on Twitter, LinkedIn and Facebook.

Media Contact
Lisa Raffensperger
Ten Bridge Communications
lisa@tenbridgecommunications.com
(617) 903-8783

Investor Contact
Chris Brinzey
Westwicke, an ICR Company
chris.brinzey@westwicke.com
(339) 970-2843


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting